BFRI
Biofrontera Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.61
+6.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 46.2M | 41.7M | 37.3M | 34.1M | 28.7M |
| Cost of Revenue | 7.2M | 8.9M | 18.6M | 17.4M | 15.2M |
| Gross Profit | 39.0M | 32.8M | 18.7M | 16.6M | 13.5M |
| Operating Expenses | |||||
| R&D Expense | 3.0M | 3.7M | 2.1M | 77.0K | — |
| SG&A Expense | 39.7M | 38.1M | 33.8M | 39.1M | 35.9M |
| General & Admin Expense | 9.7M | — | — | 37.7M | 35.9M |
| Selling & Marketing Expense | — | — | — | 1.4M | — |
| Other Expenses | 679.0K | 100.0K | — | 100.0K | (3.8M) |
| Total Operating Expenses | 43.4M | 42.0M | 35.9M | 39.3M | 32.1M |
| Cost and Expenses | 50.5M | 50.9M | 54.5M | 56.7M | 47.3M |
| Operating Income (EBIT) | (4.4M) | (9.1M) | (17.2M) | (22.7M) | (18.6M) |
| Non-Operating | |||||
| Interest Income | — | — | 30.0K | 132.0K | 175.0K |
| Interest Expense | 232.0K | 452.0K | 2.1M | 600.0K | 370.0K |
| Net Interest Income | (232.0K) | (452.0K) | (2.1M) | (468.0K) | (195.0K) |
| Other Non-Op Income/Expense | (2.0M) | (1.4M) | (527.0K) | 2.6M | 18.0M |
| Non-Operating Income (excl Interest) | 1.9M | 911.0K | (1.6M) | (3.2M) | (18.3M) |
| EBT (Pre-Tax Income) | (6.3M) | (10.5M) | (17.7M) | (20.1M) | (608.0K) |
| Income Tax Expense | 29.0K | 25.0K | 22.0K | 14.0K | 32.0K |
| Bottom Line | |||||
| Net Income | (6.4M) | (10.5M) | (17.8M) | (20.1M) | (640.0K) |
| Earnings from Cont. Ops | (6.4M) | (10.5M) | (17.8M) | (20.1M) | (640.0K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.4M) | (10.5M) | (17.8M) | (20.1M) | (640.0K) |
| Per Share | |||||
| Basic EPS | ($0.60) | ($1.04) | ($3.22) | ($13.02) | ($0.61) |
| Diluted EPS | ($0.60) | ($0.90) | ($3.22) | ($13.02) | ($0.61) |
| Revenue Per Share | $3.57 | $4.10 | $6.76 | $22.03 | $27.13 |
| Shares | |||||
| Basic Shares Outstanding | 12.9M | 10.2M | 5.5M | 1.5M | 1.1M |
| Diluted Shares Outstanding | 12.9M | 11.6M | 5.5M | 1.5M | 1.1M |
| Profitability Metrics | |||||
| EBITDA | (5.6M) | (9.2M) | (14.4M) | (18.5M) | 934.0K |
| D&A | 614.0K | 868.0K | 1.1M | 1.1M | 1.2M |
| EBIT | (6.2M) | (10.1M) | (15.6M) | (19.5M) | (238.0K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026